Genomics BioSci & Tech. Co.,Ltd. (TPE:4195)

Genomics BioSci & Tech. Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	155.47	138.3	172.58	253.03	317	107.5
Short-Term Investments	22.4	34.6	65	-	-	-
Cash & Short-Term Investments	177.87	172.9	237.58	253.03	317	107.5
Cash Growth	0.36%	-27.23%	-6.11%	-20.18%	194.90%	-81.30%
Accounts Receivable	147.73	183.71	138.86	116.1	100.02	81.75
Other Receivables	0.08	0.44	0.39	0.74	0.01	1.44
Receivables	147.81	184.15	139.25	116.84	100.02	83.2
Inventory	215.42	235.82	185.49	61.51	54.8	20.99
Prepaid Expenses	23.41	14.11	18.09	16.85	8.83	21.92
Other Current Assets	42.17	32.39	34.77	23.58	17.45	18.23
Total Current Assets	606.68	639.36	615.19	471.82	498.1	251.83
Property, Plant & Equipment	623.82	648.09	648.43	498.69	373.37	311.02
Long-Term Investments	165.05	99.79	74.65	153.98	237.96	285.83
Other Intangible Assets	9.32	6.54	5.77	1.73	0.86	1.16
Long-Term Accounts Receivable	-	-	0.64	-	-	-
Long-Term Deferred Tax Assets	-	-	-	-	-	0.07
Other Long-Term Assets	46.24	32.34	15.68	7.63	9.44	3.27
Total Assets	1,451	1,426	1,360	1,134	1,120	853.18

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	74.91	125.67	97.4	29.73	40.47	27.31
Accrued Expenses	39.94	42.54	35.4	28.7	34.5	27.54
Short-Term Debt	191.12	250.11	128.96	50	50	-
Current Portion of Long-Term Debt	62.16	60.87	35.41	4.86	12.4	3.9
Current Portion of Leases	5.78	6.5	6.43	6.51	4.75	3.39
Current Income Taxes Payable	1.65	-	-	-	0.58	-
Current Unearned Revenue	30.84	33.44	43.69	12.72	20	18.89
Other Current Liabilities	17.87	14.18	35.48	13.57	6.21	13.57
Total Current Liabilities	424.26	533.3	382.77	146.09	168.91	94.59
Long-Term Debt	270.55	301.47	328.89	214.01	153.35	75.67
Long-Term Leases	7.78	9.3	7.98	8.24	8.34	3.58
Total Liabilities	702.59	844.07	719.64	368.33	330.6	173.84

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	800	724.48	724.48	724.48	630.28	578.92
Additional Paid-In Capital	89.49	1.07	30.15	131.53	58.91	43.76
Retained Earnings	-222.66	-213.33	-204.06	-88.24	101.85	36.07
Comprehensive Income & Other	-1.49	-1.87	-1.84	-2.25	-1.91	20.59
Total Common Equity	665.35	510.34	548.73	765.51	789.13	679.34
Minority Interest	83.16	71.72	91.99	-	-	-
Shareholders' Equity	748.51	582.07	640.73	765.51	789.13	679.34
Total Liabilities & Equity	1,451	1,426	1,360	1,134	1,120	853.18

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	537.39	628.25	507.67	283.61	228.84	86.53
Net Cash (Debt)	-359.52	-455.35	-270.08	-30.58	88.17	20.96
Net Cash Growth	-	-	-	-	320.57%	-95.42%
Net Cash Per Share	-4.89	-6.29	-3.73	-0.43	1.39	0.35
Filing Date Shares Outstanding	80	72.45	72.45	72.45	64.29	60.23
Total Common Shares Outstanding	80	72.45	72.45	72.45	64.29	60.23
Working Capital	182.42	106.06	232.42	325.73	329.19	157.24
Book Value Per Share	8.32	7.04	7.57	10.57	12.27	11.28
Tangible Book Value	656.03	503.8	542.96	763.78	788.27	678.18
Tangible Book Value Per Share	8.20	6.95	7.49	10.54	12.26	11.26
Land	206.74	206.74	206.74	139.79	104.76	104.76
Buildings	267.03	266.04	256.36	211.33	144.63	134.61
Machinery	324.75	315.59	234.39	231.91	142.81	150.45
Construction In Progress	-	-	52.59	0.23	79.45	26.25
Leasehold Improvements	1.01	1.01	-	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Aug 13, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 8, 2026

Data Sources Report a data error